When will bioprinting become a therapy? Translational and regulatory challenges in urogenital tissue engineering and surgery.

Ruding M, Shajahan AB, Fossum M, Pennisi CP, Lind JU

Open source

DOI
10.3389/fbioe.2026.1865005
Published
2026
Container
Frontiers in bioengineering and biotechnology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fbioe.2026.1865005,
  title = {When will bioprinting become a therapy? Translational and regulatory challenges in urogenital tissue engineering and surgery.},
  author = {Ruding M and Shajahan AB and Fossum M and Pennisi CP and Lind JU},
  year = {2026},
  journal = {Frontiers in bioengineering and biotechnology},
  doi = {10.3389/fbioe.2026.1865005},
  url = {https://doi.org/10.3389/fbioe.2026.1865005}
}

RIS

TY  - JOUR
TI  - When will bioprinting become a therapy? Translational and regulatory challenges in urogenital tissue engineering and surgery.
AU  - Ruding M
AU  - Shajahan AB
AU  - Fossum M
AU  - Pennisi CP
AU  - Lind JU
PY  - 2026
JO  - Frontiers in bioengineering and biotechnology
DO  - 10.3389/fbioe.2026.1865005
UR  - https://doi.org/10.3389/fbioe.2026.1865005
ER  - 

APA

M, R., AB, S., M, F., CP, P., & JU, L. (2026). When will bioprinting become a therapy? Translational and regulatory challenges in urogenital tissue engineering and surgery.. Frontiers in bioengineering and biotechnology. https://doi.org/10.3389/fbioe.2026.1865005

Source records